TY - JOUR
T1 - Improvement of radiocephalic fistula maturation: rationale and design of the Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study - a randomized controlled trial
AU - Voorzaat, Bram M.
AU - van Schaik, Jan
AU - van der Bogt, Koen E. A.
AU - Vogt, Liffert
AU - Huisman, Laurens
AU - Gabreëls, Bas A. Th F.
AU - van der Meer, Irene M.
AU - van Eps, Randolph G. S.
AU - Eefting, Daniël
AU - Weijmer, Marcel C.
AU - Groeneveld, Han O.
AU - van Nieuwenhuizen, Roos C.
AU - Boom, Henk
AU - Verburgh, Cornelis A.
AU - van der Putten, Karien
AU - Rotmans, Joris I.
PY - 2017
Y1 - 2017
N2 - Non-maturation is a frequent complication of radiocephalic arteriovenous fistulas (RCAVF). In an animal model, liposomal prednisolone improved maturation of experimental fistulas. The Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study investigates if liposomal prednisolone improves RCAVF maturation. The LIPMAT study is an investigator-initiated, multicenter, double-blinded, placebo-controlled randomized controlled trial with 1:1 randomization to liposomal prednisolone or placebo. Eighty patients receiving an RCAVF will be included. The primary outcome is the cephalic vein diameter six weeks after surgery, measured by ultrasound. The LIPMAT study started in May 2016. Enrollment is expected to be completed by the end of 2017. The LIPMAT study is the first to evaluate the efficacy of liposomal prednisolone to enhance RCAVF maturation
AB - Non-maturation is a frequent complication of radiocephalic arteriovenous fistulas (RCAVF). In an animal model, liposomal prednisolone improved maturation of experimental fistulas. The Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (LIPMAT) study investigates if liposomal prednisolone improves RCAVF maturation. The LIPMAT study is an investigator-initiated, multicenter, double-blinded, placebo-controlled randomized controlled trial with 1:1 randomization to liposomal prednisolone or placebo. Eighty patients receiving an RCAVF will be included. The primary outcome is the cephalic vein diameter six weeks after surgery, measured by ultrasound. The LIPMAT study started in May 2016. Enrollment is expected to be completed by the end of 2017. The LIPMAT study is the first to evaluate the efficacy of liposomal prednisolone to enhance RCAVF maturation
U2 - https://doi.org/10.5301/jva.5000673
DO - https://doi.org/10.5301/jva.5000673
M3 - Article
C2 - 28297049
SN - 1129-7298
VL - 18
SP - 114
EP - 117
JO - Journal of Vascular Access
JF - Journal of Vascular Access
IS - Suppl. 1
ER -